Cite
HARVARD Citation
Tefferi, A. et al. (n.d.). Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American journal of hematology. 94 (1), pp. 5-9. [Online].